In November 2022, a novel FRα-directed antibody and microtubule inhibitor conjugate (mirvetuximab soravtansine) was granted accelerated approval for use in FRα positive, platinum-resistant epithelial ovarian, fallopian tube, and peritoneal cancer [72]. This evidence concerns the gene FOLR1 and peritoneum cancer.